Diabetic macular edema (DME) is a complication of diabetes in which fluid builds up in the macula, the small area at the center of the retina responsible for sharp, detailed vision. It affects roughly 5% of people with diabetes worldwide, and in U.S. adults over 40, prevalence ranges from 4% to 10% depending on racial and ethnic background and how long a person has had diabetes. DME is one of the leading causes of vision loss in working-age adults, but treatments available today can stabilize and often improve vision when caught early.
How High Blood Sugar Damages the Retina
Your retina has a protective lining of tightly sealed blood vessels called the blood-retinal barrier. Under normal conditions, this barrier controls exactly what passes from the bloodstream into the surrounding retinal tissue. Chronically elevated blood sugar disrupts that barrier through several overlapping pathways: it triggers the release of growth factors and inflammatory molecules, damages the small support cells (pericytes) that wrap around capillaries, and promotes the buildup of sugar-damaged proteins in vessel walls.
When these changes accumulate, the tiny junctions between the cells lining retinal blood vessels start to loosen. Fluid and plasma proteins leak through those gaps and into the macula. Because the leaked proteins increase the concentration of dissolved substances in the tissue, they draw even more fluid out of the vessels by osmotic pressure, much like salt draws water. The result is swelling in the part of the retina you rely on most for reading, driving, and recognizing faces.
One growth factor in particular, called VEGF, plays a central role. It signals blood vessels to become more permeable and to sprout new, fragile vessels that leak easily. Inflammatory signaling compounds add to the damage. This is why the two main classes of treatment for DME target either VEGF directly or the broader inflammatory response.
Who Is Most at Risk
Duration of diabetes and blood sugar control are the two strongest predictors. Every 1-unit increase in A1C (the blood test reflecting average blood sugar over roughly three months) is associated with a 15% higher risk of developing DME. Blood pressure matters too: each 10-point rise in systolic blood pressure adds about 6% more risk. That means someone with an A1C of 9% and uncontrolled hypertension faces meaningfully higher odds than someone with the same duration of diabetes but tighter control of both numbers.
DME can develop in people with either type 1 or type 2 diabetes, and it can appear at any stage of diabetic retinopathy, including the earliest stages when other signs of eye damage are minimal. That is one reason annual dilated eye exams are recommended for everyone with diabetes, even if vision seems fine.
What DME Feels Like
Early DME often causes no symptoms at all. The swelling can be detected on an eye exam before you notice any change in your vision. As fluid accumulation worsens, the most common complaint is blurred central vision. You might find it harder to read fine print, notice that straight lines appear wavy or distorted (a symptom called metamorphopsia), or feel that colors look faded or washed out. These distortions tend to be more pronounced when the swelling is closest to the very center of the macula, the fovea.
Peripheral vision usually stays intact, so people with DME rarely bump into things or lose awareness of their surroundings. The loss is concentrated in the detailed, high-resolution center of your visual field, which is exactly what you need for tasks that require precision.
Center-Involved vs. Non-Center-Involved DME
Doctors classify DME based on whether the swelling reaches the fovea. Center-involved DME means the fluid has encroached on that critical central point, which is more likely to cause noticeable vision loss. Non-center-involved DME sits nearby but hasn’t reached the fovea yet. This distinction directly shapes treatment decisions. Current guidelines from the American Academy of Ophthalmology recommend that eyes with center-involved DME and reduced vision (roughly 20/30 or worse) begin treatment promptly. If center-involved swelling is present but vision is still good, doctors may monitor closely and hold off on treatment until visual acuity drops, since some eyes remain stable for extended periods without intervention.
How DME Is Treated
The first-line treatment is a series of injections delivered directly into the eye, targeting VEGF. These anti-VEGF injections reduce the signal telling blood vessels to leak and can reverse much of the swelling. The procedure sounds intimidating, but the eye is numbed with drops beforehand and the needle is extremely fine. Most people describe it as brief pressure rather than sharp pain. Injections are typically given monthly at first, then spaced out as the swelling stabilizes.
Newer formulations are extending the time between injections significantly. A higher-dose version of one widely used anti-VEGF drug has been shown to maintain the same visual gains when given every 12 to 16 weeks instead of every 8. Another newer drug targets both VEGF and a second molecule involved in vessel instability, also allowing longer intervals between visits. For many patients, this means fewer trips to the retina specialist each year while still keeping the swelling controlled.
Steroid Implants
For eyes that don’t respond well to anti-VEGF therapy (called refractory DME), steroid implants offer an alternative. These are tiny devices placed inside the eye that slowly release anti-inflammatory medication over weeks to months. They require fewer repeat procedures than anti-VEGF injections, which can reduce the overall treatment burden. The trade-off is a higher risk of elevated eye pressure, which in some cases can lead to glaucoma progression or the need for pressure-lowering treatment. Cataracts are also a known long-term concern, though shorter studies have not always shown a statistically significant difference compared to anti-VEGF therapy. Your eye doctor will weigh these risks if switching to steroids becomes part of the conversation.
What to Expect During Treatment
Most people begin to notice vision stabilizing within the first few months of anti-VEGF injections, and many see measurable improvement. Response varies. Some eyes recover several lines on the vision chart, while others hold steady without further decline. Consistency matters: skipping or delaying injections during the early loading phase often leads to worse outcomes because the swelling rebounds quickly.
Treatment for DME is typically long-term. Many patients continue some form of injection therapy for years, though the frequency usually decreases over time. Retinal imaging (most commonly optical coherence tomography, a painless scan that takes seconds) is used at each visit to measure the thickness of the macula and guide decisions about when the next injection is needed.
Protecting Your Vision Beyond Injections
Because blood sugar and blood pressure are directly tied to DME risk and progression, managing both aggressively is one of the most impactful things you can do alongside eye treatment. Lowering A1C by even one point meaningfully reduces the chance of developing new or worsening edema. Keeping systolic blood pressure under control provides an additional, independent layer of protection.
Cholesterol management, maintaining a healthy weight, and not smoking also support retinal health, though their individual effect sizes on DME specifically are less precisely quantified. The broader principle holds: the same cardiovascular risk factors that damage blood vessels throughout the body damage the blood vessels in your retina. Treating DME effectively almost always involves both the retina specialist and the primary care team working in parallel.